EARLY Treatment with azilsartan compared to ACE-inhibitors in anti-hypertensive therapy – rationale and design of the EARLY hypertension registry

Documenti analoghi

• Azilsartan compared to ACE inhibitors in anti-hypertensive therapy: one-year outcomes of the observational EARLY registry
  di: Gitt, Anselm K., et al.
  Pubblicazione: (2016)
• Patients With Newly Diagnosed Hypertension Treated With the Renin Angiotensin Receptor Blocker Azilsartan Medoxomil vs Angiotensin‐Converting Enzyme Inhibitors: The Prospective EARLY Registry
  di: Schmieder, Roland E., et al.
  Pubblicazione: (2015)
• The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry
  di: Bramlage, Peter, et al.
  Pubblicazione: (2015)
• Is Azilsartan More Effective in Younger Than in Older Patients? An Explorative Analysis of the Prospective EARLY Registry
  di: Schmieder, Roland E., et al.
  Pubblicazione: (2016)
• Achievement of recommended glucose and blood pressure targets in patients with type 2 diabetes and hypertension in clinical practice – study rationale and protocol of DIALOGUE
  di: Gitt, Anselm K, et al.
  Pubblicazione: (2012)